Unihealth (UNIHEALTH) H1 FY27: Beds Up From 120 to 400, More Planned
Unihealth Hospitals Limited (NSE: UNIHEALTH) - Share price: ₹492 (22 Nov 2026, screener.in) - Market cap: ₹844 crore (22 Nov 2026, screener.in) - P/E: 33.8 (peer median 54.4, screener.in peer table) - ROCE: 24.5% (screener.in; the company's own H1 FY27 ROCE is 6.76%, explained below) - 52-week high / low: ₹820 / ₹255
Unihealth Hospitals (UNIHEALTH) grew H1 FY27 revenue 15% to ₹76.45 crore while its beds rose from 120 to 400, but margins fell.
The Mumbai company runs UMC Hospitals in Uganda and India. In its H1 FY27 investor presentation (half year to 30 September 2026), the growth driver is clear: more beds. The profit side is not yet following. This article reads the presentation and the screener.in numbers side by side.
What does Unihealth Hospitals (UNIHEALTH) do?
Unihealth was founded in 2010 and is headquartered in Mumbai. Its brand is UMC Hospitals. It was formerly called Unihealth Consultancy Limited. It listed on NSE Emerge (the exchange's SME platform) in September 2023. Shareholders have approved moving to the NSE Mainboard and listing on BSE. No date has been given.
The company has four hospitals with 400 beds:
Hospital Country Beds Started ------------ UMC Victoria Hospital, Kampala Uganda 120 2017 UMC Hospital, Entebbe Uganda 30 1 Feb 2026 UMC Hospital, Navi Mumbai India 50 2 Oct 2025 UMC Hospitals, Nashik India 200 1 Sep 2026
It also runs 5 clinics in Uganda and 2 outreach clinics in Navi Mumbai. It treats over 1,50,000 patients a year, and has 600+ employees and 250+ doctors. Three smaller lines sit beside the hospitals: healthcare consultancy (1,300+ beds under management across India, the Middle East and Africa), pharma exports to Uganda, Tanzania and Nigeria, and medical travel from Africa and the Middle East to India.
Unihealth H1 FY27 results: sales up 15%, EBITDA down 25%
₹ crore (consolidated) H1 FY26 H1 FY27 Change ------------ Revenue from operations 66.67 76.45 +14.7% Total opex 38.79 57.60 +48.5% EBITDA 34.62 25.91 -25.2% EBITDA margin 49.77% 33.31% -16.5 points PAT to owners 15.11 14.22 -5.9% PAT margin 21.72% 18.28% -3.4 points EPS (₹) 9.79 8.77 -10.4%
Costs rose three times faster than sales. Management says the cause is three new sites that opened in about 12 months (Navi Mumbai in Oct 2025, Entebbe in Feb 2026, Nashik in Sep 2026), with new clinics on top. Depreciation rose from ₹3.85 crore to ₹5.72 crore and finance cost from ₹1.18 crore to ₹1.84 crore.
The margin reset did not start in H1 FY27. The half year before it already showed it:
Period EBITDA EBITDA margin --------- H1 FY26 ₹34.62 crore 49.77% H2 FY26 ₹24.20 crore 35.88% H1 FY27 ₹25.91 crore 33.31%
On a longer view, the full-year consolidated EBITDA margin rose from 34.58% in FY23 to 42.93% in FY26 as the Uganda business grew. FY26 revenue was ₹131.99 crore, EBITDA ₹58.82 crore and PAT to owners ₹25.83 crore.
Why the Nashik hospital and 400 beds make the growth visible
Beds are the capacity that earns future revenue. The company had 120 beds before FY26. It now has 400. The 200-bed Nashik hospital opened on 1 September 2026, so H1 FY27 holds only one month of it. It has 4 modular operating theatres and a robotic surgery unit. The first hip replacement and the first newborn-ICU patient were treated within 15 days of opening.
The Navi Mumbai hospital has already added firsts: its first robotic surgery (May 2026) and its first IVUS-guided heart procedure (June 2026).
What happens next depends on how fast these beds fill. Management's own plan says:
- Occupancy, patient volumes and service mix should improve as the new sites mature, which should lift margins over the medium term. - The target is 25% EBITDA for the Indian boutique hospitals and a steady 35% EBITDA in Africa. - Victoria Hospital in Kampala runs at 62% occupancy, per the strategic roadmap.
This is management's own forward-looking view. It is not a promise.
Is Unihealth's Uganda business the profit engine?
Uganda gave 78% of revenue in H1 FY27 and India 19%.
₹ crore H1 FY26 H2 FY26 H1 FY27 ------------ Uganda 63.24 52.03 64.27 India 8.99 15.96 15.50
Most of the year-on-year growth came from India. Uganda grew about 2%. India grew 72% against H1 FY26, but it fell slightly against H2 FY26.
UMC Victoria Hospital is the first ISO-certified, UN-accredited private hospital in Uganda and the preferred hospital of the Uganda People's Defence Force. It has a 10-year corporate income tax holiday. In FY26 on its own it earned a 44.23% EBITDA margin and a 38.03% PAT margin, with net profit up 56%.
On 2 September 2026 Unihealth raised its stake in Victoria Hospital from 50% to 99.81%. It bought the extra 49.81% through a share swap, so no cash left the company. This is why reported profit looks low: Victoria was consolidated for only part of the half year. The company shows a pro forma PAT to owners of ₹23.02 crore, against ₹14.22 crore reported, as if it had owned 99.81% for the whole period. Treat the pro forma figure as the company's own illustration.
Unihealth's cash flow, receivables and debt
₹ crore (consolidated) FY25 FY26 H1 FY27 ------------ Cash from operations 3.31 5.69 23.83 Net worth 141.81 197.96 216.43 Trade receivables not in the deck 123.38 114.39
- Cash from operations reached ₹23.83 crore in six months, above the ₹21.52 crore profit before minority interest. This is a good sign. In FY26 it was only ₹5.69 crore against ₹25.83 crore of profit. - Receivables are high. Trade receivables are ₹114.39 crore against annualised revenue of about ₹153 crore. By my own calculation that is roughly 270 debtor days, and about 340 days at FY26 year-end. The deck does not give debtor days. This is the figure to watch. - Debt is low. Total debt is ₹28.37 crore (long-term ₹22.68 crore, short-term ₹5.69 crore), a debt-to-equity ratio of 0.13. Interest cover in FY26 was 20.79 times. - Cash and bank balance was ₹12.17 crore. - Fixed assets rose from ₹93.97 crore at FY26 to ₹165.54 crore, because of the new hospitals and lease assets under Ind-AS. - Cash flow from investing was -₹74.45 crore in H1 FY27 (the Victoria stake and new hospitals), funded by +₹52.03 crore from financing.
The company's own H1 FY27 ROCE is 6.76%, against 15.56% a year ago. The reason is that the asset base grew fast while the new hospitals have not yet filled. FY26 ROCE was 21.28% and ROE 22.96%. The 24.5% on screener.in is a trailing figure that does not yet carry the full cost of the new hospitals.
How the valuation compares
Company (screener.in, 22 Nov 2026) Price (₹) P/E Market cap (₹ crore) Sales growth, latest quarter ROCE ------------------ Unihealth Hospitals 492 33.8 844 14.7% 24.5% Narayana Hrudayalaya 1,943.7 43.9 39,722 73.0% 15.5% Apollo Hospitals 9,200 58.4 1,32,282 23.0% 17.5% Fortis Healthcare 825 58.1 62,284 17.3% 13.5% Max Healthcare 1,081 74.1 1,05,217 20.3% 14.7% Global Health 1,480.2 61.5 39,799 33.6% 17.4%
Unihealth's P/E is below every large peer on screener.in. The peers are about 45 to 160 times bigger by market cap and run mostly in India. Unihealth is a ₹844 crore company with most of its profit in Uganda, so the comparison shows a gap, not a verdict. The stock trades about 40% below its 52-week high of ₹820 and about 93% above its low of ₹255.
What management plans next
These are the company's own forward-looking statements.
- Pune: find and finalise a site for a 100-150 bed multispecialty hospital by the end of FY2026-27. It would complete a "Golden Triangle" of Mumbai, Nashik and Pune. - India: 3+ more hospitals and 300+ more in-patient beds in the next 24-36 months. - Africa: 300+ more in-patient beds in 24-36 months, through a hub-and-spoke model in Uganda and expansion into Tanzania and Kenya. UMC Hospital Mwanza in Tanzania is "set to commission soon". No date is given. - Network goal: managing director Dr. Anurag Shah says "Our near-term ambition is to establish a network of more than 1,000 commissioned beds across India and Africa." The deck also mentions 1,000+ India beds by FY2030-31. - Margins: 25% EBITDA for Indian boutique hospitals and 35% for Africa, over the medium term. - Solar power: a power purchase agreement with solar parks in Maharashtra is being pursued. No timeline is given. - Listing: application to move to the NSE Mainboard and list on BSE. No date is given. - Numbers: management gave no revenue or profit target.
Key people named in the deck: Dr. Akshay Parmar (Founder and Managing Director), Dr. Anurag Shah (Founder and Executive Director) and Parag Shah (Executive Director and CFO). The deck does not give their ages or past careers, so this article does not either.
Risks in Unihealth's growth story
- Margin dilution. Nashik opened only on 1 September 2026. Its ramp-up cost sits ahead of its revenue. - Uganda concentration. Uganda is 78% of revenue. A rule change, political event or new competitor there would hit hard. The 10-year tax holiday at Victoria is also finite. - Currency. Much of the revenue is in Ugandan shillings and other African currencies. The deck shows UGX at ₹0.0249. A weak shilling lowers rupee profit. - High receivables. About ₹114 crore is owed to the company, which is large against revenue. - Execution. 300+ new beds in India and 300+ in Africa in 24-36 months, on top of an India hospital business that is only about a year old. - Operating in six countries raises compliance cost, and pharma distribution depends on imports. - Thin disclosure. This article does not cover shareholding, fund buying or the company's past record against its earlier guidance. Check those before you decide.
The lesson Unihealth has built the beds first and the profit will follow only if they fill. H1 FY27 shows the cost of that bet: revenue up 15%, EBITDA down 25%. The next two results will show whether Nashik and Navi Mumbai fill.
Note: I am not a SEBI-registered investment advisor. This article is for educational purposes only and is not investment advice. Please consult a registered financial advisor before making investment decisions.
Sources
- https://nsearchives.nseindia.in/corporate/UNIHEALTH21112026163435Presentationsigned.pdf